132 related articles for article (PubMed ID: 38615806)
1. Nanomicelles empower natamycin in treating fungal keratitis: An in vitro, ex vivo and in vivo study.
Sathe P; Kailasam V; Nagarjuna V; Sharma H; Velpandian T; Garg P; Nirmal J
Int J Pharm; 2024 May; 656():124118. PubMed ID: 38615806
[TBL] [Abstract][Full Text] [Related]
2. Natamycin solid lipid nanoparticles - sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: preparation and optimization.
Khames A; Khaleel MA; El-Badawy MF; El-Nezhawy AOH
Int J Nanomedicine; 2019; 14():2515-2531. PubMed ID: 31040672
[TBL] [Abstract][Full Text] [Related]
3. Corneal targeted nanoparticles for sustained natamycin delivery and their PK/PD indices: an approach to reduce dose and dosing frequency.
Chandasana H; Prasad YD; Chhonker YS; Chaitanya TK; Mishra NN; Mitra K; Shukla PK; Bhatta RS
Int J Pharm; 2014 Dec; 477(1-2):317-25. PubMed ID: 25455776
[TBL] [Abstract][Full Text] [Related]
4. Reduced administration frequency for the treatment of fungal keratitis: a sustained natamycin release from a micellar solution.
Guo Y; Karimi F; Fu Q; G Qiao G; Zhang H
Expert Opin Drug Deliv; 2020 Mar; 17(3):407-421. PubMed ID: 32009483
[No Abstract] [Full Text] [Related]
5. Natamycin Ocular Delivery: Challenges and Advancements in Ocular Therapeutics.
Mascarenhas M; Chaudhari P; Lewis SA
Adv Ther; 2023 Aug; 40(8):3332-3359. PubMed ID: 37289410
[TBL] [Abstract][Full Text] [Related]
6. The preparation and therapeutic effects of β-glucan-specific nanobodies and nanobody-natamycin conjugates in fungal keratitis.
Liu X; Sui J; Li C; Wang Q; Peng X; Meng F; Xu Q; Jiang N; Zhao G; Lin J
Acta Biomater; 2023 Oct; 169():398-409. PubMed ID: 37579912
[TBL] [Abstract][Full Text] [Related]
7. Optimization of β-cyclodextrin consolidated micellar dispersion for promoting the transcorneal permeation of a practically insoluble drug.
Sayed S; Elsayed I; Ismail MM
Int J Pharm; 2018 Oct; 549(1-2):249-260. PubMed ID: 30077759
[TBL] [Abstract][Full Text] [Related]
8. Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis; in vitro/in vivo and histopathological studies.
El-Nabarawi MA; Abd El Rehem RT; Teaima M; Abary M; El-Mofty HM; Khafagy MM; Lotfy NM; Salah M
Drug Dev Ind Pharm; 2019 Jun; 45(6):922-936. PubMed ID: 30744431
[TBL] [Abstract][Full Text] [Related]
9. Cell penetrating peptides as efficient nanocarriers for delivery of antifungal compound, natamycin for the treatment of fungal keratitis.
Jain A; Shah SG; Chugh A
Pharm Res; 2015 Jun; 32(6):1920-30. PubMed ID: 25467959
[TBL] [Abstract][Full Text] [Related]
10. Fabrication of a drug delivery system that enhances antifungal drug corneal penetration.
Li J; Li Z; Liang Z; Han L; Feng H; He S; Zhang J
Drug Deliv; 2018 Nov; 25(1):938-949. PubMed ID: 29658325
[TBL] [Abstract][Full Text] [Related]
11. Carboxyvinyl Polymer and Guar-Borate Gelling System Containing Natamycin Loaded PEGylated Nanolipid Carriers Exhibit Improved Ocular Pharmacokinetic Parameters.
Patil A; Lakhani P; Taskar P; Avula B; Majumdar S
J Ocul Pharmacol Ther; 2020; 36(6):410-420. PubMed ID: 32315560
[No Abstract] [Full Text] [Related]
12. Natamycin versus voriconazole for fungal keratitis.
Retamal J; Ordenes-Cavieres G; Grau-Diez A
Medwave; 2018 Dec; 18(8):e7388. PubMed ID: 30562337
[TBL] [Abstract][Full Text] [Related]
13. Niosomes: Do They Increase the Potency of Topical Natamycin Ketorolac Formula in Treating Aspergillus Keratitis? An Experimental Study.
El-Mofty HM; El-Nabarawi MA; Abd El Rehem RT; Teaima MH; Abary MYS; Salah M; Lotfy NM
J Ocul Pharmacol Ther; 2020 Sep; 36(7):545-554. PubMed ID: 32357092
[No Abstract] [Full Text] [Related]
14. [Fungal keratitis caused by Scedosporium apiospermum: first report from Turkey].
Kalkan Akçay E; Açıkgöz ZC; Can ME; Celikbilek N; Dereli Can G; Cağıl N
Mikrobiyol Bul; 2013 Oct; 47(4):727-33. PubMed ID: 24237443
[TBL] [Abstract][Full Text] [Related]
15. Overcoming the Stromal Barrier of the Cornea with a Peptide Conjugate Nano-Assembly to Combat Fungal Keratitis.
Ju X; Wu L; Gao N; Tian Y; Lu G; Gao Y; Zhao S; Niu Z; Yang R
Adv Healthc Mater; 2023 Apr; 12(10):e2202409. PubMed ID: 36588425
[TBL] [Abstract][Full Text] [Related]
16. Drug-loaded mesoporous carbon with sustained drug release capacity and enhanced antifungal activity to treat fungal keratitis.
Gu L; Li C; Lin J; Wang Q; Yin M; Zhang L; Li N; Lin H; You Z; Wang S; Li D; Zhao G
Biomater Adv; 2022 May; 136():212771. PubMed ID: 35929310
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic response time of topical voriconazole 1% and intrastromal voriconazole 0.05% versus topical natamycin 5% monotherapy in Fusarium keratitis in rabbit.
Edwar L; Janna YM; Rozaliyani A; Louisa M
Mycoses; 2020 Oct; 63(10):1128-1132. PubMed ID: 32780874
[TBL] [Abstract][Full Text] [Related]
18. Natamycin in the treatment of keratomycosis: correlation of treatment outcome and in vitro susceptibility of fungal isolates.
Pradhan L; Sharma S; Nalamada S; Sahu SK; Das S; Garg P
Indian J Ophthalmol; 2011; 59(6):512-4. PubMed ID: 22011503
[TBL] [Abstract][Full Text] [Related]
19. A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis.
Prajna NV; John RK; Nirmalan PK; Lalitha P; Srinivasan M
Br J Ophthalmol; 2003 Oct; 87(10):1235-7. PubMed ID: 14507756
[TBL] [Abstract][Full Text] [Related]
20. Zero order delivery of itraconazole via polymeric micelles incorporated in situ ocular gel for the management of fungal keratitis.
Jaiswal M; Kumar M; Pathak K
Colloids Surf B Biointerfaces; 2015 Jun; 130():23-30. PubMed ID: 25889081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
